Abstract
Introduction
Endoscopic Ultrasound (EUS) is relatively new technology that has been shown to be a highly sensitive method for the detection of pancreatic masses. [1] It is more sensitive than conventional computed tomography (CT) scan for detecting small pancreatic tumors (<3.0cm) and determining their resectability based on vessel invasion. [2] Early detection is important as tumor size is an independent predictor of improved prognosis. [3] EUS-guided fine-needle aspiration biopsy (EUSFNAB) is useful and accurate modality for characterizing lesions from the pancreas, lymph node, gastrointestinal tract wall, retro peritoneum, liver, biliary tree and adrenal glands. [4] EUS-FNAB can be performed on small lesions, offering an opportunity for early detection of tumors, the staging of malignancies and in some instances, helping to avoid unnecessary surgeries. The reported results of pancreatic EUS-FNA vary in the range of 64-95% for sensitivity, 75-100% for specificity and 78-95% for diagnostic accuracy. [5] Several factors can affect the results of EUS-FNA, such as the experience of the endo-sonographer, the position of the endoscope, the diameter of the needle, the number of passes, and the presence of an onsite cytopathologist. [6] Furthermore, core biopsy specimens for assessing architectural features may be essential for diagnosing certain neoplasm, such as lymphomas and stromal cell tumors. [7] However cost and staffing limitations frequently limit the availability f an on-site cytopathologist at many centers. [8] www.jmscr.igmpublication. Although EUS is highly sensitive in detecting pancreatic solid masses, its ability to differentiate between inflammatory masses and malignant disease is limited.1with the advent of curvilinear echo endoscope stransgastric and transduodenal EUS-FNAB of the pancreas have become a reality. [9] EUS-with FNAB has become an important technique of gastroenterologists for the diagnosis of pancreatic adeno-carcinoma before chemotherapy and/ or surgery. EUS-FNAB, with its ability to obtain a tissue diagnosis, has increased the accuracy of EUS in the diagnosis of pancreatic adeno carcinoma. The diagnostic accuracy of EUS-FNAB was enhanced in prospective, multicenter studies and demonstrates that EUS-FNAB is a highly accurate diagnostic test for solid neoplasm of the pancreas. [10] The survival rate of patients with these tumors is extremely poor, with an overall 5-year survival rate of less than 5%, 12 making it one of the biggest "cancer killers". [13] Therefore early and accurate diagnosis is vital for improving the efficacy of therapeutic intervention. In the current study, we prospectively evaluated the cellular yield of EUS-FNAB in patients with solid pancreatic masses who were clinically suspected to have pancreatic carcinoma. We also evaluated the clinical significance of anatypical or suspicious cytologic diagnosis and investigated the causes of falsenegative results with the aim to prospectively evaluate the yield of EUS-FNAB in the diagnosis of patients presenting with solid pancreatic lesion In our study patients presenting with solid pancraetic lesion found that 67% of the lesions were located in head of the pancreas, 15% were located in the uncinate, 13% were located in the body and 5% were located in the tail. 
Material

FNAC diagnosis in Patients with Solid Pancreatic Masses
According to Mohamad A. Eloubeidi et al (2003)18, in evaluating the yield of EUS-FNAB in the diagnosis of patients presenting with solid pancreatic lesions found that 65% of the lesions were situated in the head of pancreas, 12% of it were located in the uncinate, 17% in the body and 6% in the tail. According to Guilia A Zamboni et al (2009) Histopathologic analysis of the core samples revealed 76 biopsy samples sufficient for a diagnosis of pancreatic ductal adenocarcinoma M Vossetal (2000)21EUS-FNAB was feasible in 90 patients (adenocarcinomas, n = 59; neuroendocrine tumours, n = 15; various neoplasms, n = 6; pancreatitis, n = 10), and analysable material was obtained in 73. 17the cumulative yield after repeat EUS-FNA for definite pancreatic adenocarcinoma was 7 (16%). Faming Zhang (2016)15 Pancreatic adenocarcinoma was the final diagnosis in 87.6% of patients. Out of the 67 patients with malignant mass, 55 (82.1%) patients were correctly diagnosed by EUS -FNAB as malignant, while 9 (13.4%) were wrongly suggested as benign by EUS -FNAB and out of the 4 suspicious lesion 3 were malignant on final diagnosis. Out of 13 patients with benign pancreatic mass, 12 (92.3%) were correctly diagnosed to have benign lesion and one patient had suspicious finding. Diagnostic yield of EUS -FNAB is considering suspicious result as non-diagnostic in patients with Solid Pancreatic Masses. Specificity was found to be 100% Sensitivity of 82.09% PPV of 100% NPV was found to be low 52%. This implicates that if EUS FNAB finding suggests benign lesion, the patients need to be cautiously followed up as there is 48% chance that the lesion may turn up to be malignant. The overall diagnostic accuracy of EUS FNAB was found to be 88.5% i.e. 88.5% of pancreatic masses are correctly classified as malignant / benign by EUS FNAB. 23 , Among small masses, the diagnostic rate and sensitivity for biopsies guided using CT (100% and 100%, respectively) were not significantly different from those for biopsies guided using endoscopic sonography (90.9% and 93.8%, respectively). For large masses, the diagnostic rate & sensitivity (96.6% & 92.3% respectively) for biopsies guided using CT were not significantly different from those for biopsies guided using endoscopic sonography (83.3% and 50%, respectively).
According to P. Thomas Cherian et al (2010)24, there were 78 pancreatic lesions, of which 65 were true positives (TP), 11 true negatives (TN) and two FN, giving an overall accuracy of 97% (76/78). Of nine periampullary lesions, 2 were TP, 6 were TN and 1 was FN, giving an overall accuracy of 89% (8/9). The sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV) and accuracy of EUS-FNA for pancreatic and periampullary lesions combined were 96%, 100%, 100% [95% confidence interval (CI) 95-100%], 85% (95% CI 62-97%) and 97%, respectively. NPV was found to be low (57.14%) i.e. among patients suggested to have benign lesion by EUS FNAB, only 57.14% were finally diagnosed to have benign lesion, and rest 42.86% were wrongly suggested as benign. This implicates that if EUS FNAB finding suggests benign lesion, the patients need to be cautiously followed up as there is 42.86% chance that the lesion may turn up to be malignant. The overall diagnostic accuracy of EUS FNAB was found to be 88.5% i.e. 88.5% of pancreatic masses are correctly classified as malignant / benign by EUS FNAB. Our study observed that the adenocarcinoma was the most common diagnosis in solid pancreatic masses found in 40 (50%) of patients. Most common benign finding was chronic pancreatitis found in 21 (26.2%) patients. Neuroendocrine carcinoma was found in 5 (6.3%) patients. Malignant epithelial and poorly differentiated metastatic carcinoma were reported in 3 (3.8%) pancreatic masses. Anaplastic giant cell carcinoma and spindle cell neoplasm were found in only 1 patient each. Suspicious for malignant finding on FNAC was reported in 4 patients. Similar observation was found in the study conducted by M Voss et al (2000)21, which found that EUS-FNAB was feasible in 90 patients (adenocarcinomas, as 59; neuroendocrine tumours, as 15; various neoplasms, as 6; pancreatitis, n = 10), and analyzable material was obtained in 73. Tumour size (> or <25 mm in diameter) did not influence the ability to obtain informative biopsy samples. Diagnostic accuracy was 74.4% (adenocarcinomas, 81.4%; neuroendocrine tumours, 46.7%; other lesions, 75%; p<0.02). Overall, the diagnostic yield in all 99 patients was 68%. According to Sean D. Paulsen et al (2005) 20 who observed that 92/ 107 masses analyzed to have truepositive results. Histopathology analysis of the core samples revealed 76 biopsy samples sufficient for a diagnosis of pancreatic ductal adenocarcinoma. Benign biopsy findings cannot be used to exclude the presence of a neoplasm, and repetition of a biopsy should be considered if there is high clinical suspicion of malignancy. Veronika Gagovic (2012)14there were 21 patients (11%) with initial FNA suspicious for malignancy who required a second attempt at tissue acquisition via repeat EUS-FNA, EUS-guided core biopsy or confirmed pathology based on surgical resection specimen. Out of 21 patients, 11 confirmed NPPA neoplasms, while 10 as primary pancreatic adenocarcinoma. In this study we observed that most of the benign pancreatic lesions were found in males (76.1%). Malignant pancreatic lesions were found more in males (58.2%) as compared to females (41.8%). No significant difference was found in the gender distribution of benign and malignant pancreatic lesions (p=0.339). Carlo Fabbri et al (2014) 25 found that the overall sensitivity, specificity, positive predictive value, negative predictive value, and accuracy were 80%, 100%, 100%, 40%, and 82%, respectively. They have suggested that EUS-FNB of small pancreatic lesions using a 22-gauge ProCore needle is effective and safe which supports our hypothesis that EUS-FNB is highly useful in establishing the nature of small pancreatic lesions. Alexandra Kalogeraki et al (2016)26EUS-FNAB shows the sensitivity, specificity and accuracy of EUS-FNAB for pancreatic lesions range from 64% to 94%, 71% to 100% and 78% to 95% respectively. In different studies retrieved from PUBMED database since last 5 years, the sensitivity, specificity, positive predictive value, negative predictive value and accuracy of EUS-FNA for pancreatic solid masses were reported to be as 78 to
